Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Qing Wu, Wei Qian, Xiaoli Sun, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 134

Showing 1-25 of 134 citing articles:

Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 126
Recent advances in targeted strategies for triple-negative breast cancer
Shuangli Zhu, Yuze Wu, Bin Song, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 103
Focal adhesion kinase: from biological functions to therapeutic strategies
Ximin Tan, Yuheng Yan, Bin Song, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 51
The role of RNA methylation in tumor immunity and its potential in immunotherapy
Yan Li, Haoer Jin, Qingling Li, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 26
BRD4-targeted photodegradation nanoplatform for light activatable melanoma therapy
Shiman Lu, Zhaoqing Shi, Chendi Ding, et al.
Biomaterials (2025) Vol. 317, pp. 123101-123101
Closed Access | Times Cited: 2
Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy
Mohammed Hawash
Biomolecules (2022) Vol. 12, Iss. 12, pp. 1843-1843
Open Access | Times Cited: 67
Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
Seyed Hossein Kiaie, Hossein Salehi‐Shadkami, Mohammad‐Javad Sanaei, et al.
Journal of Nanobiotechnology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 35
Drug Delivery Systems for Localized Cancer Combination Therapy
Ryan Woodring, Elizabeth G. Graham-Gurysh, Eric M. Bachelder, et al.
ACS Applied Bio Materials (2023) Vol. 6, Iss. 3, pp. 934-950
Open Access | Times Cited: 30
LncRNA-encoded peptides in cancer
Yaguang Zhang
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 13
Small molecule agents for triple negative breast cancer: Current status and future prospects
Yan Ou, Mengchao Wang, Qian Xu, et al.
Translational Oncology (2024) Vol. 41, pp. 101893-101893
Open Access | Times Cited: 12
Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy
Binglei Zhang, Jianxiang Shi, Xiaojing Shi, et al.
Drug Resistance Updates (2024) Vol. 74, pp. 101068-101068
Closed Access | Times Cited: 12
Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer
Chengpei Zhu, Yunchao Wang, Ruijuan Zhu, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 12
Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products
Yalan Zhou, Siqi Peng, Huizhen Wang, et al.
Genes (2024) Vol. 15, Iss. 4, pp. 468-468
Open Access | Times Cited: 11
Nucleic acid-based drugs for patients with solid tumours
Sebastian G. Huayamares, David Loughrey, Hyejin Kim, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 6, pp. 407-427
Closed Access | Times Cited: 11
Synthesis and biological evaluation of novel benzothiazole derivatives as potential anticancer and antiinflammatory agents
Xuemei Xu, Zhaojingtao Zhu, Siyu Chen, et al.
Frontiers in Chemistry (2024) Vol. 12
Open Access | Times Cited: 8
Newer Therapeutic Approaches in Treating Alzheimer’s Disease: A Comprehensive Review
Radhakrishna Reddi Sree, Manjunath Kalyan, Nikhilesh Anand, et al.
ACS Omega (2025) Vol. 10, Iss. 6, pp. 5148-5171
Open Access | Times Cited: 1
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study
Yuankai Shi, Yanzhen Guo, Xingya Li, et al.
The Lancet Respiratory Medicine (2025)
Closed Access | Times Cited: 1
Eliminating VEGFA+ tumor-associated neutrophils by antibody-drug conjugates boosts antitumor immunity and potentiates PD-1 immunotherapy in preclinical models of cervical cancer
Shili Yao, Lu Sun, Ye Lu, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs
Yanbai Li, Shanshan Huo, Zhe Yin, et al.
mBio (2023) Vol. 14, Iss. 5
Open Access | Times Cited: 18
Research progress on non-protein-targeted drugs for cancer therapy
Yiwen Zhang, Lu Lu, Feifeng Song, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 16
Activated T cell-derived exosomes for targeted delivery of AXL-siRNA loaded paclitaxel-poly-L-lysine prodrug to overcome drug resistance in triple-negative breast cancer
Chuanrong Chen, Ming Shen, Xiaofeng Wan, et al.
Chemical Engineering Journal (2023) Vol. 468, pp. 143454-143454
Closed Access | Times Cited: 16
Six‐Membered Aromatic Nitrogen Heterocyclic Anti‐Tumor Agents: Synthesis and Applications
Jiatong Li, Ao Gu, Xiao‐Mei Nong, et al.
The Chemical Record (2023) Vol. 23, Iss. 12
Closed Access | Times Cited: 16
Targeting CD8+ T cells with natural products for tumor therapy: Revealing insights into the mechanisms
Yuke Wang, Yan Zeng, Wenyong Yang, et al.
Phytomedicine (2024) Vol. 129, pp. 155608-155608
Closed Access | Times Cited: 7
Retracted and republished from: “The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs”
Yanbai Li, Shanshan Huo, Zhe Yin, et al.
mBio (2024) Vol. 15, Iss. 5
Open Access | Times Cited: 6
Advancements in Cancer Immunotherapies
Ruchi Roy, Sunil Kumar Singh, Sweta Misra
Vaccines (2022) Vol. 11, Iss. 1, pp. 59-59
Open Access | Times Cited: 26
Page 1 - Next Page

Scroll to top